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Abstract: Alcohol dehydrogenases catalyse the conversion of a large variety of ketone substrates
to the corresponding chiral products. Due to their high regio- and stereospecificity, they are key
components in a wide range of industrial applications. A novel alcohol dehydrogenase from
Comamonas testosteroni (CtADH) was identified in silico, recombinantly expressed and purified,
enzymatically and biochemically investigated as well as structurally characterized. These studies
revealed a broad pH profile and an extended substrate spectrum with the highest activity for
compounds containing halogens as substituents and a moderate activity for bulky–bulky ketones.
Biotransformations with selected ketones—performed with a coupled regeneration system for the
co-substrate NADPH—resulted in conversions of more than 99% with all tested substrates and with
excellent enantioselectivity for the corresponding S-alcohol products. CtADH/NADPH/substrate
complexes modelled on the basis of crystal structures of CtADH and its closest homologue suggested
preliminary hints to rationalize the enzyme’s substrate preferences.
Keywords: alcohol dehydrogenase; asymmetric synthesis; biotransformation; protein crystallography;
protein structure; short chain dehydrogenase/reductase
1. Introduction
Oxidoreductases have a wide substrate scope and can act on organic substrates including alcohols,
ketones/aldehydes, amines and inorganic substrates including small ions such as sulphite [1–4].
Therefore, they are a valuable class of enzymes to synthesize complex chiral products under mild reaction
conditions and with high chemo-, regio- and stereoselectivity [5,6]. The resulting enantiomerically pure
chemicals are essential chiral building blocks for the production of chiral pharmaceuticals, drugs or
flavours [7,8].
NAD(P)(H)-dependent alcohol dehydrogenases (ADHs) represent one of the largest groups
of biotechnologically applied oxidoreductases. In particular, the so-called short-chain reductases/
Catalysts 2020, 10, 1281; doi:10.3390/catal10111281 www.mdpi.com/journal/catalysts
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dehydrogenases (SDR) which are spread among all kingdoms of life [9] provide a large fund of valuable
biocatalysts. The application range of SDR enzymes and other ADHs has been enlarged in recent years
by several promising efforts:
(i) ADHs require nicotinamide cofactors—NAD(H) or NADP(H)—to perform their function.
These compounds (in particular NADP+ and NADPH) are expensive, which can be a limiting factor
for industrial biocatalysis. A modern solution of the problem is the application of an integrated
efficient recycling system that allows process operation under economic conditions. For this
purpose, two cofactor regeneration systems—enzyme-coupled and substrate-coupled—have
been developed and described in detail [10–12]. Furthermore, the co-substrate specificity might
be changed from NADP(H)- to NAD(H) dependence by site-directed mutagenesis, which then
allows the utilization of the less expensive cofactor NAD(H) [13].
(ii) Several ADHs are comparatively pH- and thermostable [14,15], robust against stress imposed
by non-aqueous solvents [16] and can be optimized in these directions. Thermostable and
solvent-resistant enzymes are particularly valuable if hydrophobic substrates with solubility
problems in aqueous media are processed [17].
(iii) The spectrum of substrates accepted by ADHs is rather broad ranging—for example, from small
alcohols such as isopropanol [18] via sugars [12] to complex steroids [19,20]—and is often
accompanied by a significant and synthetically attractive enantioselectivity. Accordingly, in case
an important reaction step in asymmetric synthesis is accomplished, rather than mutating a
well-known ADH, it is often more promising to screen for a novel ADH activity with the required
profile [1]. With the growing number of annotated but not further characterized ADHs revealed
by genome sequencing, it becomes increasingly attractive to perform such screening efforts in
silico [21].
The enzymatic production of chiral secondary alcohols from asymmetric ketones is a particularly
important and ambitious task. Many ADHs for the transformation of “small-bulky” ketones were
described in the past [13,22], whereas ADHs accepting “bulky-bulky” ketones are much less abundant.
Two enzymes with this profile were found in Ralstonia sp. DSM 6428 (RasADH) [23,24] and in
Sphingobium yanoikuyae DSM 6900 (SyADH) [25]; both enzymes have been structurally characterized in
a complex with NADPH [26].
In this study, we supplement this collection with an ADH from Comamonas testosteroni (CtADH).
Comamonas testosteroni belongs to the betaproteobacteria, which have versatile metabolic capacities
and possess a wide spectrum of substrate utilization [27]. Its complete genome is sequenced and
available [28,29]. The rationale to choose C. testosteroni as source of a novel ADH with valuable
properties was its occurrence in polluted environments and its ability to convert xenobiotics. Strains of
C. testosteroni have been paid great attention due to their capability of utilizing testosterone and derivates
such as bile acids and other xenobiotic compounds [19,20,30–32]. For example, C. testosteroni CNB-1 has
been successfully applied in environment bioremediation to degrade 4-chloronitrobenzene in soil [33].
We describe here the in silico identification, heterologous expression and biochemical
characterization of CtADH. Kinetic and structural analysis were performed to develop a deeper
understanding of the structure–activity relationship of this enzyme towards bulky–bulky as well as
halogenated substrates. In addition, the impact of organic solvents on the stability of CtADH and a pH
profile of the catalytic activity are explored.
2. Results and Discussion
2.1. Identification of the Alcohol Dehydrogenase Gene
In GenBank [34] (entry WP_003056551.1), CtADH is classified as a putative short-chain
dehydrogenase/reductase (SDR). The gene comprises 789 bp and encodes 262 amino acids. The closest
homologue of CtADH with known 3D-structure (sequence identity 77%) and thus representing a
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reference enzyme is SyADH. A sequence alignment with SyADH and other related ADHs (Figure 1)
confirms the classification of CtADH as a member of the SDR family and encompasses the typical
Rossmann fold with the glycine motif at the N-terminus and conserved catalytic triad residues.
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recombinant  plasmid was  expressed  in  E.  coli  BL21(DE3)  at  different  temperatures  and media, 
Figure 1. Multiple sequence alignment of CtADH, SyADH (genbank: EU4 7523.1), PapADH
(EU4275 2.1), RasADH (ACB78 91.1), LkADH (AY267012.1) and 7α-HSDH (AJP09756.1),
illustrated with ENDs ript [35] including structural i or ation from SyADH [26]. Secondary structure
elem nts are presented on top: helices with squiggles, beta strands with rrows and turns with TT
letters. Positions with high similarity are boxed in blue and written in red; absolutely conserved regions
are boxed in red. The glycine-motif G X XG is indicated as described and the a i ci r si es of
the catalytic triade are marked ith a star.
2.2. Cloning and Heterologous Overexpression of CtADH
Standard cloning techniques were used to create the recombinant plasmid pET28a_CtADH(C)
with a hexahistidine affinity purification motif (His-tag), fused to the C-terminus of the protein.
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The recombinant plasmid was expressed in E. coli BL21(DE3) at different temperatures and media,
revealing the best expression in TB medium at 25 ◦C (Figure S1a). The crude and purified enzymes were
analysed by SDS-PAGE (Figure S1b). The over-expressed CtADH was clearly displayed (Figure S1a).
The band was estimated at about 25 kDa, which is in good accordance with the calculated molecular
weight of 29.7 kDa. Already in the crude extract, the high over-expression of this enzyme could be
demonstrated (Figure S1b).
2.3. Substrate Specificity, Kinetic Parameters and Enantioselectivity of CtADH
The activity of CtADH in reduction direction was studied with linear aliphatic, aromatic ketones,
halogenated and “bulky-bulky” compounds (Table 1) and the oxidation with a variety of alcohols
(Table 2). The substrate specificity of the enzyme was determined by spectrophotometric assays for
both reaction directions.
In general, CtADH showed a very broad substrate range as figured in Table 1. The highest activity
was obtained with 2,2,2-trifluoroacetophenone (entry 12, 127.7 U mg−1) and 2,3-pentandione (entry
15, 85.9 U mg−1). Many other aliphatic compounds were also converted such as 2-heptanone and
4-nonanone. In addition, halogenated, cyclic and even “bulky-bulky” compounds turned out to be
suitable substrates and were converted with, at least in part, high activities. Reductions of halogenated
compounds are of importance because those substrates are often intermediates in the synthesis of active
pharmaceuticals ingredients (APIs) [36,37]. Furthermore, “bulky-bulky” substrates, such as ethyl
benzoylformate, are well accepted with an especially high activity in this case (entry 10, 82.9 U mg−1).
“Bulky-bulky” ketones with both bulky substituents (larger than ethyl) to the carbonyl carbon are
challenging to be reduced by most ADHs due to the size limitation of the small binding pocket.
Table 1. Spectrophotometrically determined activities for the reduction of various ketone substrates by
CtADH. The activities were obtained by use of the standard spectrophotometric assay. (* marks the
chiral center of the product.)
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# Substrate Concentration [ ] Spec. Activity [U mg−1]
1 2-aminoacetophenone hydrochloride 0.1
2 4-phenyl-2-butanone 10 8.1
3 ethyl 2-oxo-4-phenylbutyrate 10 0.4
4 4-chlorobutyrophenone <10 3.7
5 acetophenone 10 0.8
6 propiophenone 1.4
7 (R)-carvone <10 0.5
8 ethyl 4-chloroacetoacetate 10 3.4
9 cyclohexanone 10 1.2
10 ethyl benzoylformate 1 82.9
11 ethyl acet acetate 5 18.5
12 2,2,2-triflu roacetoph none 0 127.7
13 4-hydroxy-2-butanone 50 0.3
14 2-heptanone 10 6.1
15 2,3-pentandione 50 85.9
16 4-nonanone <10 2.8
17 2-octanone <10 5.
18 ethyl 4,4,4-trifluoroacetoacetate 50 4.6
19 2-chlorocyclopentanone 25 12.1
20 2-chlorocyclohexanone 25 64.2
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Table 2. Spectrophotometrically determined activities for the oxidation of various alcohol substrates by
CtADH. The activities were obtained by use of the standard spectrophotometric assay with a substrate
concentration of 10 mM in all cases. (* marks the chiral center of the product.)
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For the direction of the xidation, only aromatic substrates wer tested (Table 2). The best activity
was obtained with 4-phenyl-2-butanol (entry 21, 3.4 U mg-1). Further investigation of the oxidativ
reaction is necessary to gain accurate information regarding the substrate profil .
The kinetic parameters of the purified C ADH for the substrate propiophenone (reduction)
and (S)-1-ph nylethanol (oxid tion), together with the cofactor NADPH and NADP+, respectively,
were m asured at 27.5 (reduct on) and 28.8 ◦C (oxidation) at pH 6, respectively (Figure S2).
For propiophenone, the Michaelis–Menten constant (KM) was determined to be 0.62 ± 0.07 mM and the
maximum specific velocity (Vmax) was 0.53 ± 0.02 U mg−1 (Figure S2a). For the oxidative reaction with
(S)-1-phenylethanol, the Michaelis–Menten constant (KM) was determined to be 1.72 ± 0.05 mM and
the maximu spec fic veloc ty (Vmax) wa 0.21 ± 0.01 U mg−1 (Figure S2b). For the cofa tor NADP ,
together with 1 mM propiophenone, the determined kinetic constants were KM = 13.9 ± 1.1 µM and
Vmax = 0.39 ± 0.01 U mg−1 (Figure S2c).
The asymmetric reduction of ketones to their corresponding alcohols in the presence of CtADH as
biocatalyst were performed in a monophasic aqueous system and compared to the biotransformations
with the recombinant SyADH (Table 3).
Table 3. Reduction of selected ketones by CtADH and SyADH. Degrees of conversion and ee values
were determined by chiral GC. (* marks the chiral center of the product.)
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Substrate
CtADH SyADH
Conversion [%] Selectivity [ee] Conversion [%] Selectivity [ee]
acetophenone >99 (S) 97% >99 (S) 98%
ethyl benzoylformate >99 (S) 65% >99 (S) 57%
ethyl 4-chloroacetoacetate >99 (S) 96% >99 (R) 41%
4-chlorobutyrophenone >99 (S) 99% >99 (S) 99%
2,2,2-trifluoroacetophenone >99 (S) 77% >99 (S) 58%
ethyl 4,4,4-trifluoroacetoacetate >99 (S) 99% >99 (S) 83%
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All tested substrates were reduced to the corresponding (S)-alcohols with high enantioselectivity
(over 96% ee) except for ethyl benzoylformate and 2,2,2-trifluoracetophenone, which were reduced with
an enantioselectivity of 65% and 77% ee, respectively. This result indicates that CtADH is an (S)-specific
ADH. It is noteworthy that in comparison, the SyADH showed a decreased enantioselectivity for
most of the tested substrates. The ketone ethyl 4-chloroacetoacetate was even converted to the
(R)-enantiomer with 41% ee. According to these results, CtADH appears to be a promising catalyst
candidate for biotransformations of a broad range of diverse substrates with high enantioselectivity.
Future experiments will serve to explore if the attractive combination of high selectivity and conversion
holds true at higher substrate concentrations as well.
2.4. pH-Profile of Catalytic Activity and Effect of Organic Solvents on CtADH Stability
To test the dependence of CtADH activity on the pH-value and organic solvents, the reduction of
propiophenone was measured under various conditions. For the determination of the pH optimum,
three buffers with overlapping pH ranges were used (citrate acid/phosphate buffer (pH 4.5 to 7.5),
Tris/HCl buffer (pH 8.0 to 9.0) and bicine buffer (pH 8.0 to 12.1)) (Table S2). The enzyme showed a
good activity (>90%) over a broad pH range from pH 5.5 to 8.5 (Figure 2a). This correlates well with
the fact that the melting point of CtADH exceeds 40 ◦C in most applied buffers except those at pH 5
or lower (Figure S3). The activity optimum was determined to be at pH 7.0 in citrate acid/phosphate
buffer (Figure 2a). This broad pH range of the reduction reaction represents an advantage when using
CtADH as a biocatalyst.
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2.5. Structural Characterization of CtADH
Extensive crystallization efforts with CtADH led to an orthorhombic and a tetragonal crystal form.
The crystals X-rays to resolutions of about 2.0 Å and 2.2 Å and led to structures of acceptable quality
(Table S1) comprising three (orthorhombic structure) or two (tetragonal structure) crystallographically
independent CtADH protomers per asymmetric unit.
The structures contain the apo-form of CtADH without any substrate or co-substrate ligands
despite the presence of such compounds in the crystallization drops. This deficit may contribute to the
fact that in all five CtADH monomers, a functionally critical part—the helical α5/η7 region that covers
the active site in a catalytically fully competent enzyme/substrate complex—is disordered and not
defined by electron density (Figure 3a). Otherwise, the tertiary structure of CtADH shows the typical
open α/β topology of SDR enzymes based on a classical Rossmann fold: a central seven-stranded
parallel β-sheet to which eight α-helices of different lengths are attached on both sides (Figure 3a).
Two of these helices (α4 and α5) seamlessly merge into each other (Figure 1).
Like SyADH, CtADH contains a non-canonical helix α9 in its C-terminal segment (Figure 3a). This
helix sticks out from the main domain since it has a special double role at the level of the quaternary
structure: as typical for SDR enzymes, the large helices α4/α5 and α6 function as a dimerization
module and form a four-helix bundle with a second CtADH monomer (Figure 3b); yet, in contrast to
most SDR enzymes (but similar to SyADH), the particular helix α9 crosses over to the second subunit
and forms a helical pair with its counterpart within the dimer. In this way, the helix α9 stabilizes the
dimeric architecture (Figure 3b); simultaneously, however, it blocks the surface used by the majority
of SDR enzymes to coordinate a second dimer and thus to establish a homotetramer with D2 point
symmetry. In Figure 3b, this is illustrated with the R-specific alcohol dehydrogenase from Lactobacillus
brevis (LbRADH) [13,22] which accordingly contains a much shorter C-terminal segment (Figure 3a).
To rationalize the essentials of CtADH’s substrate and stereospecificity, we modelled a ternary
complex of the enzyme with the substrate n-pentyl phenyl ketone and the co-substrate NADPH in
silico (Figure 3a). To this end, we took over NADPH from its binary complex structure with SyADH
(PDB-ID 4BMV); with respect to the substrate, we adapted the modelling strategy described for the
SyADH/NADPH/n-pentyl phenyl ketone complex [26]. In a plausible catalytic complex, the carbonyl
group of the ketonic substrate must be properly located and oriented relative to the co-substrate
NADPH and to the catalytic key residues Ser140 and Tyr153. Therefore, the substrate molecule was
modelled in such a way into a kind of substrate-binding tunnel that the carbonyl O-atom is in hydrogen
bonding distance to the side chains of Ser140 and Tyr153 and that the carbonyl C-atom is close enough
to the C4-atom of the nicotinamide ring to allow hydride transfer (Figure 3a,b).
Further, similar to what had been done for SyADH [26], we placed n-pentyl phenyl ketone
such that its re-plane faces NADPH. This orientation, in which the phenyl ring is embedded in a
hydrophobic environment within the outer part of the substrate-binding tunnel formed by Val141,
Leu148, Ala184/185 and Trp191 (Figure 3a), would lead to the product S-1-phenyl hexanol and is thus
consistent with the preference of CtADH for the (S)-enantiomer of 1-phenyl ethanol, a CtADH substrate
in oxidation direction (Table 2). R-1-phenyl ethanol, however, is oxidized under CtADH catalysis as
well, albeit with a significantly lower specific activity (Table 2). Thus, CtADH prefers to accommodate
a bulky phenyl substituent in the outer substrate binding tunnel as indicated in Figure 3c,d, but can
essentially place it alternatively as well, namely at the inner region of the tunnel occupied by the
n-propyl chain in Figure 3c,d. This spaciousness at both sides of the tunnel fits to the bulky–bulky
substrate profile of CtADH indicated among others by the fact that propiophenone is a better substrate
than acetophenone (Table 1). In contrast, in an enzyme such as LbRADH that prefers acetophenone
and other small-bulky ketones as substrates [13,40], the space at the outer tunnel region is restricted by
the side chains of Tyr189 and Ile143 (Figure 3d) which excludes the binding of a bulky moiety and
forces ketonic substrates into an orientation that necessarily leads to (R)-alcohol products.
The example of LbRADH shows that the substrate profile and the stereospecificity can be
strongly correlated. Accordingly, for bulky–bulky ADHs such as CtADH or SyADH with small spatial
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limitations on both sides of the substrate-binding tunnel, one would expect only a low enantioselectivity.
Interestingly (and most attractively for application purposes), however, this is not the case: the data set
in Table 3 suggests that CtADH is even more enantioselective than SyADH and prefers the formation of
the S-enantiomer of an alcoholic reaction product more strongly than the latter. If space restrictions such
as in LbRADH are not sufficient to enforce this enantioselectivity, more subtle molecular interactions
within the substrate-binding tunnel must exist that favour one specific orientation of a ketonic substrate
over the other. Possibly, the two substitutions between CtADH and SyADH illustrated in Figure 3c
(Leu148/Phe148 and Gly92/Ala92) are critical for the enhanced enantioselectivity of CtADH. Mutational
studies and, in particular, experimental complex structures of the enzymes with substrates or significant
inhibitors are required to allow a deeper rationalization of these connections.
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Figure 3. Structure of CtADH. (a) Overview of a CtADH monomer with secondary structure elements
labelled according to the sequence alignment in Figure 1. F r comparison, parts of the structures of
the SyADH/NADPH complex (PDB-ID 4BMV [26]) and of ap -LbRADH (PDB-ID 1NXQ [22]) were
depicted after structural overlay on CtADH. (b) Dimerization of CtADH via a central four-helix bundle
(α4/5 plus α6), assisted by the non-canonical helices α9, from both subunits. To illustrate how the helix
α9 couple blocks the tetramerization surface of typical tetrameric SDR enzymes, two subunits of the
LbRADH tetramer [22] wer drawn after superimposition of the ot er two subunits (no shown) on the
CtADH dimer. (c) Active site region of an in silico model of CtADH in complex with NADPH and the
substrate n-pentyl phenyl ketone. Two side chains of SyADH different from CtADH were drawn with
black C-atoms after structural overlay of the proteins. (d) Substrate-binding tunnel of CtADH occupied
with n-pentyl phenyl ketone (in silico model). To illustrate the generous space supply in the outer part
of the substrate-binding tunnel of CtADH, two LbRADH side chains were drawn (black C-atoms) that
restrict the space in this region of LbRADH significantly.
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3. Materials and Methods
3.1. Origin of Chemicals
All used chemicals were of high analytical grade and purchased from Sigma Aldrich (Steinheim,
Germany) and Carl Roth (Karlsruhe, Germany). Coenzymes were bought from Biomol (Hamburg,
Germany). Ni-NTA resin was purchased from MCLAB (San Francisco, CA, USA) and restriction
enzymes, Phusion™-Polymerase, Plasmid isolation kits as well as T4 ligase from ThermoScientific
(Waltham, MA, USA). Oligonucleotids were synthesized by EurofinsMWG (Ebersberg, Germany).
3.2. Identification, Cloning and Heterologous Expression of CtADH and SyADH
The protein sequence of the “bulky-bulky” alcohol dehydrogenase SyADH (GenBank [34] entry
EU427523) [17,26] was used as the query sequence for BLAST analysis [41] for the identification of
potential alcohol dehydrogenase candidates. After analysis of the results, focusing on the Comamonas
species, a gene from Comamonas testosteroni with a similarity of 77% was chosen as the gene of interest.
This gene (GenBank: WP_003056551.1) was amplified from the Comamonas testosteroni strain DSM 38
via polymerase chain reaction (PCR), cloned into the pET28a plasmid and transformed into Escherichia
coli BL21(DE3) (see supporting information).
For protein overexpression, TB auto induction medium, TB as well as LB medium were tested.
Auto induction media containing 2 g L−1 lactose, 0.5 g L−1 glucose and 50 µg mL−1 kanamycin
were inoculated with 1% of an overnight preculture. The cells were incubated at 37 ◦C for 2 h and
then for 72 h at 15 ◦C. TB and LB media with appropriate kanamycin were inoculated with 1%
of an overnight preculture, and the induction of the gene was started by the addition of 500 µM
isopropyl-β-d-thiogalactopyranoside (IPTG) when the OD600 reached 0.4 to 0.6. Cells were harvested
after 18 h at 25 ◦C for LB and TB media, and additionally at 30 or 37 ◦C for the TB media, and stored at
−20 ◦C until further use.
The SyADH gene was chemically synthesized in codon-optimized form by GeneArt (ThermoFisher,
Germany). A hexahistidine-tag was fused to the N-terminus and bacterial expression was performed
equally to the one of the CtADH.
3.3. Purification of CtADH and SyADH
Purified protein was obtained by Ni-NTA immobilized metal affinity chromatography (IMAC).
The column was equilibrated with 25 mL lysis buffer (10 mM imidazole, 300 mM NaCl, 50 mM
NaH2PO4, pH 8.0). The cell lysate containing his-tag fusion protein was applied on the column and
washed with 50 mL washing buffer (25 mM imidazole, 300 mM NaCl, 50 mM NaH2PO4, pH 8.0).
The bound protein was eluted with 10 mL elution buffer (250 mM imidazole, 300 mM NaCl, 50 mM
NaH2PO4, pH 8.0). After a desalting step with a PD10 column (Sephadex G25, GE healthcare, Munich,
Germany), the enzyme was stored in 100 mM citrate-phosphate buffer pH 6.0 and kept at 4 ◦C until use.
For the purpose of crystallization, the CtADH purification was supplemented with an additional
size exclusion step in 25 mM Hepes, 150 mM NaCl, pH 7.5.
3.4. Crystallization and Structure Determination of CtADH
CtADH crystals were grown by the vapour diffusion sitting drop method at 20 ◦C by mixing 1 µL
of protein solution with 1 µL of reservoir solution. The optimized reservoir compositions providing
crystals suitable for data collection were 20% (v/v) polyethylene glycol 1500; 0.1 M sodium-HEPES,
pH 7.5, in case of the orthorhombic crystals; and 10% (w/v) polyethylene glycol 4000, 0.2 M MgCl2,
60 mM K2SO4, 0.1 M MES buffer and pH 6.5 for the tetragonal crystals. The protein was crystallised in
the presence of the co-substrate NADP+.
Oil and oil with addition of 2,3-butanediol were used as cryo-condition prior to flash freezing the
crystals in liquid nitrogen for the tetragonal and orthorhombic crystal, respectively. X-ray diffraction
data sets of the two CtADH crystals were collected at beamline ID23-1 of the European Synchrotron
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Radiation Facility (ESRF) in Grenoble, France, using a wavelength of 0.97970 Å (orthorhombic CtADH
crystal) and at beamline PXIII of the Swiss Light Source (SLS) in Villigen, Switzerland, using a
wavelength of 1.00000 Å (tetragonal CtADH crystal). The data collection temperature was 100 K.
The data were processed with the AUTOPROC toolbox (version 1.0.5, Global Phasing Limited,
Cambridge, UK) using default settings [42]. The pipeline applied XDS (BUILT 20200417) [43] for
indexing and integration, POINTLESS (version 1.11.21) [44] and AIMLESS (version 0.7.4) [45] from the
CCP4 suite (version 7.1.000) [46] for space group determination and scaling and finally STARANISO
(version 2.3.36) [47] for anisotropy analysis.
The CtADH structures were solved with molecular replacement using PHASER (version 2.8.3) [48]
within PHENIX (version 1.18.2-3874) [49] and the SyADH structure PDB-ID 4BMV [26] as search model.
The structures were optimized with several rounds of PHENIX refinement [49] followed by manual
modelling with COOT (version 0.9) [50] and deposited at the PDB with the codes 6ZE0 (orthorhombic
structure) and 6ZDZ (tetragonal structure). The illustrations in Figure 3 were prepared with PYMOL,
version 1.7.0.3 [51].
3.5. Enzyme Activity Assays
Assays for ADH activity were performed spectrophotometrically by measuring the consumption
of the cofactor NADPH. The standard assay was performed in 100 mM citrate-phosphate buffer at a pH
value of 6.0 with 10 mM propiophenone (unless otherwise stated). The specific activity of the purified
CtADH (0.1 mg/mL) was determined for various substrates in concentrations between 1 and 50 mM in
100 mM citrate-phosphate buffer (pH 6.0) with 0.2 mM NADPH for reductions and 0.2 mM NADP+ for
oxidations, respectively. All spectrophotometric measurements were performed at least in triplicates.
Additionally, the KM-values for the substrates propiophenone and phenyl-1-ethanol as well as
for the cofactor NADP(H) were determined. All measurements were carried out in a total volume of
300 µL in microtiter plates. In 100 mM citrate-phosphate buffer, pH 6.0, containing propiophenone
(0.01 mM–13.59 mM) purified CtADH with a concentration of 0.13 mg/mL was added. For phenyl-1-ethanol
(0.01 mM–12.96 mM), 0.25 mg/mL of purified enzyme was added. The specific activity was determined
after adding NADPH (0.36 mM) for propiophenone and phenyl-1-ethanol through measuring the change
of absorbance at 340 nm over 1 min at different temperatures (propiophenone 27.4 ◦C, phenyl-1-ethanol
29.4 ◦C) using a Tecan Reader. The KM-values of NADP+ and NADPH (0.01 mM–0.35 mM) were
determined measuring the specific activity of CtADH with propiophenone as substrate at a fixed
concentration of 2 mM at 27.5 ◦C for NADP+ and 28.8 ◦C for NADPH with 0.1 mg/mL purified CtADH.
3.6. Effect of Organic Solvents and pH on the Stability and Activity of CtADH
The effect of various organic solvents (methanol, ethanol, isopropanol, dimethyl sulfoxide (DMSO),
ethyl acetate, dichloromethane, acetonitrile, toluene, methyl tert-butyl ether (MTBE)) on the stability of
purified CtADH was evaluated by incubating the enzyme with either 10, 25 or 50% (v/v) of the specified
organic solvent at 22 ◦C for 2 h. For the water-soluble solvents, the samples were shaken at 1000 rpm,
and for the water insoluble solvents, they were inverted with 13 rpm with a laboratory rotator from IKA
(Loopster basic). The CtADH activity was then assayed using propiophenone (10 mM) as substrate in
100 mM citrate-phosphate buffer, pH 6, at 25 ◦C. Relative activity was calculated based on a control
in which buffer was added instead of the organic solvent. To evaluate the pH-profile of CtADH,
the enzyme solution was diluted in different buffers, covering a broad pH range, and incubated for
10 min at room temperature. Details are described in chapter 6.2 of the Supporting Information.
All spectrophotometric measurements were performed at least in triplicates.
3.7. Determination of the Enantioselectivity
The enantioselectivity of CtADH in the reduction of different ketones was examined with the
use of D-glucose and a modified heat purified glucose dehydrogenase (GDH) from Bacillus subtilis
to achieve continuous NADPH recycling [52]. The different biotransformations were performed as
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follows: 10 mM substrate, 20 mM D-glucose, 0,2 mM NADP+, 3 U GDH, 10 mg purified CtADH
in a final volume of 1.5 mL 100 mM citrate-phosphate buffer, pH 6.0, incubated at 30 ◦C. After 2 h,
the reaction mixture was extracted with ethyl acetate (3 mL) and analysed by chiral GC (Shimadzu
GC-2010 Plus). The experimental details of the GC analyses and the measured retention times are
given in chapter 7 of the Supporting Information.
4. Conclusions
In this study, we report the in silico identification, cloning, heterologous expression and
functional as well as structural characterization of an NADPH-dependent alcohol dehydrogenase
from C. testosteroni (CtADH). The enzyme displays a wide pH tolerance and a broad substrate range
including bulky–bulky ketones and is, thus, particularly attractive for applications as a biocatalyst in
the context of sustainable biotechnology. Furthermore, CtADH shows an excellent enantioselectivity
to (S)-alcohols, which makes it a suitable candidate as a biocatalyst for the production of chiral
building blocks. The CtADH crystal structures of this work allow a basic understanding of the
enzyme’s bulky–bulky substrate profile. In conclusion, this work emphasizes that in silico screening to
identify novel enzymes with desired characteristics is a good alternative to complex and expensive
mutagenesis studies.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4344/10/11/1281/s1,
1. Cloned sequence of alcohol dehydrogenase from Comamonas testosteroni (DSM 38). 2. Molecular cloning of
CtADH. 3. Preparation of crude extract. 4. Figure S1: SDS-Page analysis of protein expression of CtADH in
E. coli BL21(DE3) with different conditions (a) and SDS-Page gel picture from purification of CtADH. 5. Table S1:
X-ray diffractometry. 6. Enzyme assays; Figure S2: Michaelis–Menten diagrams of CtADH towards propiophenone
and NADPH (reduction) as well as (S)-phenylethanol (oxidation). 7. Analytical methods; Table S3: List of used
GC-methods; Table S4: List of measured retention times. 8. Figure S3: Thermal shift assay of CtADH.
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